![Dalton Smart](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Dalton Smart
Amministratore Delegato presso
HARPOON THERAPEUTICS, INC.
Patrimonio netto: 1 M $ in data 31/07/2026
Profilo
Dalton E.
Smart has held executive roles including Chief Executive Officer, President, Director, and Vice President-Tax at multiple pharmaceutical and biotechnology companies such as Harpoon Therapeutics, Calporta Therapeutics, Prometheus Biosciences, Imago BioSciences, Caraway Therapeutics, Afferent Pharmaceuticals, Acceleron Pharma, ArQule, and Tilos Therapeutics.
Mr. Smart has also served as Senior Vice President-Finance & Global Controller at Merck & Co., Inc. since 2023 and is a Central Board Member at Junior Achievement of New Jersey, Inc. Mr. Smart is currently Chief Executive Officer at Harpoon Therapeutics, Inc., Calporta Therapeutics, Inc., Prometheus Biosciences, Inc., and Imago BioSciences, Inc.; President & Director at Caraway Therapeutics, Inc., Acceleron Pharma, Inc., and ArQule, Inc.; President, Director & Vice President-Tax at Tilos Therapeutics, Inc.; Chief Executive Officer & Director at Afferent Pharmaceuticals, Inc.; Senior Vice President-Finance & Global Controller at Merck & Co., Inc.; Central Board Member at Junior Achievement of New Jersey, Inc.; and Director at Terns Pharmaceuticals, Inc. starting in 2026.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 05/05/2026 | 9.388 ( 0% ) | 1 M $ | 31/07/2026 |
Posizioni attive di Dalton Smart
| Società | Posizione | Inizio |
|---|---|---|
| MERCK & CO., INC. | Comptroller/Controller/Auditor | 04/12/2023 |
| HARPOON THERAPEUTICS, INC. | Amministratore Delegato | - |
| ACCELERON PHARMA INC. | Presidente | - |
| ARQULE, INC. | Presidente | - |
| TERNS PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 05/05/2026 |
| PROMETHEUS BIOSCIENCES, INC. | Amministratore Delegato | - |
| IMAGO BIOSCIENCES, INC. | Amministratore Delegato | - |
Junior Achievement of New Jersey, Inc.
 Junior Achievement of New Jersey, Inc. Part of JA Worldwide, Inc., Junior Achievement of New Jersey, Inc. is a company based in Princeton, NJ. James W. Horne has been the CEO of the company since 2022. | Direttore/Membro del Consiglio | - |
Caraway Therapeutics, Inc.
 Caraway Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company for the treatment of genetically defined neurodegenerative and rare diseases | Presidente | - |
| ░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░░░ | - |
| ░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░░░ | - |
| ░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░ | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
80
Relazioni di 1° grado
12
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 12 |
|---|---|
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
ArQule, Inc.
 ArQule, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that researches and develops therapeutics to treat cancers & rare diseases | Health Technology |
Acceleron Pharma, Inc.
 Acceleron Pharma, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company which develops protein therapeutics for cancer and orphan diseases | Health Technology |
Afferent Pharmaceuticals, Inc.
 Afferent Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops novel, selective drugs for the treatment of a range of debilitating neurogenic disorders | Health Technology |
Junior Achievement of New Jersey, Inc.
Junior Achievement of New Jersey, Inc. Part of JA Worldwide, Inc., Junior Achievement of New Jersey, Inc. is a company based in Princeton, NJ. James W. Horne has been the CEO of the company since 2022. | |
Imago BioSciences, Inc.
 Imago BioSciences, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company that develops medicines for the treatment of myeloproliferative neoplasms and bone marrow diseases | Health Technology |
Calporta Therapeutics, Inc.
 Calporta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops small molecule agonists | Health Technology |
Harpoon Therapeutics, Inc.
 Harpoon Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage immunotherapy company that develops T-cell engagers to treat cancer and other diseases | Health Technology |
Tilos Therapeutics, Inc.
 Tilos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops antibody therapeutics for cancer, fibrosis and autoimmune disease | Health Technology |
Prometheus Biosciences, Inc.
 Prometheus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops medicines for immune-mediated diseases | Health Technology |
Terns Pharmaceuticals, Inc.
 Terns Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops small-molecule product candidates to address serious diseases including oncology and obesity | Health Technology |
Caraway Therapeutics, Inc.
Caraway Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company for the treatment of genetically defined neurodegenerative and rare diseases | Health Technology |
